Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

691 articles

Research Review

Showing 1–2 of 2 articles · Keyword: Gemcitabine Clear keyword

Journal of biological engineering2026ResearchNon-viral Gene DeliveryDrug Delivery

1. Aptamer-functionalized exosomes co-delivering miR-934 inhibitor and gemcitabine for targeted pancreatic cancer therapy

Bi J, Ye L, Shi H, Jian Z, Li R, Jiang Z, Et Al.

Pancreatic cancer remains a malignancy with limited treatment efficacy and high resistance to chemotherapy. miR-934 was identified as an oncogenic miRNA significantly upregulated in pancreatic cancer, promoting tumor progression, epithelial-mesenchymal transition (EMT), and chemoresistance by targeting the tumor…

Read the article

Biomacromolecules2026ResearchDrug Delivery

2. Gemcitabine Delivery and Nucleolin-Targeting Nanocarriers Based on N6L-Functionalized Polyelectrolyte Complexes and Layer-By-Layer Lipid Nanoparticles

Larue L, Brissault B, Chesneau C, Modjinou T, Leroy E, Hamadi S, Et Al.

Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to chemotherapy due to dense stromal barriers. Although gemcitabine remains the standard treatment, its efficacy is limited. Combining it with the pseudopeptide N6L has shown synergistic effects, but administering them individually in biological systems…

Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.